West Pharmaceutical CEO buys more shares; Saudi Arabian pharma manufacturing to grow; NeuroVive does deal for South Korea;

> West Pharmaceutical Services ($WST) CEO Mark Green bought 18,300 shares of the company's stock at an average price of $54.89 per share last week in an open market transaction last week, giving him direct ownership of 18,300 shares. Article

> Spimaco's CEO, Fahad bin Ibrahim Al Khalaf, sees even greater growth of pharmaceutical manufacturing in Saudi Arabia in the coming years. Article

> NeuroVive Pharmaceutical said its Asia group has signed a deal with Sanofi's ($SNY) local affiliate to develop and market CicloMulsion in South Korea. Release